Arrowhead Pharma Files Q4 2024 Report

Ticker: ARWR · Form: 10-Q · Filed: Feb 10, 2025 · CIK: 879407

Sentiment: neutral

Topics: 10-Q, SEC filing, compliance

Related Tickers: ARWR

TL;DR

**ARWR filed its 10-Q for Dec 31, 2024. All good on reporting.**

AI Summary

Arrowhead Pharmaceuticals, Inc. filed its quarterly report for the period ended December 31, 2024. The company is registered in Delaware and trades on The Nasdaq Global Select Market under the symbol ARWR. This filing confirms they have met all reporting requirements for the preceding 12 months and the past 90 days, and have submitted all required Interactive Data Files electronically.

Why It Matters

This filing is a routine update confirming Arrowhead Pharmaceuticals' compliance with SEC reporting obligations, providing transparency to investors about their financial and operational status.

Risk Assessment

Risk Level: low — This is a standard quarterly report confirming compliance with filing requirements, not indicating any new risks.

Key Players & Entities

FAQ

What is the primary purpose of this Form 10-Q filing?

The primary purpose is to provide a quarterly report on the financial and operational status of Arrowhead Pharmaceuticals, Inc. for the period ended December 31, 2024.

Has Arrowhead Pharmaceuticals, Inc. met its filing obligations for the past 12 months?

Yes, the filing indicates that Arrowhead Pharmaceuticals, Inc. has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.

What is the trading symbol for Arrowhead Pharmaceuticals, Inc. common stock?

The trading symbol for Arrowhead Pharmaceuticals, Inc. common stock is ARWR.

On which exchange is Arrowhead Pharmaceuticals, Inc. common stock traded?

Arrowhead Pharmaceuticals, Inc. common stock is traded on The Nasdaq Global Select Market.

Has Arrowhead Pharmaceuticals, Inc. submitted all required Interactive Data Files electronically?

Yes, the filing indicates that Arrowhead Pharmaceuticals, Inc. has submitted electronically every Interactive Data File required pursuant to Rule 405 of Regulation S-T during the preceding 12 months.

Filing Stats: 4,452 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2025-02-10 16:02:51

Key Financial Figures

Filing Documents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS 1 Consolidated Balance Sheets 1 Consolidated Statements of Operations and Comprehensive Loss 2 Consolidated Statements of Stockholders' Equity 3 Consolidated Statements of Cash Flows 4

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 5

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 22

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 27

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 27

— OTHER INFORMATION

PART II — OTHER INFORMATION 29

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 29

RISK FACTORS

ITEM 1A. RISK FACTORS 29

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 29

DEFAULTS UPON SENIOR SECURITIES

ITEM 3. DEFAULTS UPON SENIOR SECURITIES 29

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 29

OTHER INFORMATION

ITEM 5. OTHER INFORMATION 29

EXHIBITS

ITEM 6. EXHIBITS 30 SIGNATURE 31

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Arrowhead Pharmaceuticals, Inc. Consolidated Balance Sheets (in thousands, except per share amounts) December 31, 2024 September 30, 2024 (unaudited) ASSETS Current assets: Cash, cash equivalents and restricted cash $ 53,889 $ 102,685 Accounts receivable 2,500 — Available-for-sale securities, at fair value 499,046 578,276 Prepaid expenses 9,366 9,537 Other current assets 5,735 4,973 Total current assets 570,536 695,471 Property, plant and equipment, net 387,069 386,032 Intangible assets, net 8,137 8,562 Right-of-use assets 44,869 45,255 Other assets 3,083 4,482 Total Assets $ 1,013,694 $ 1,139,802 LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 14,457 $ 11,388 Accrued expenses 59,401 63,017 Accrued payroll and benefits 11,275 21,989 Lease liabilities 6,560 6,342 Credit facility 1,625 — Other liabilities 440 432 Total current liabilities 93,758 103,168 Long-term liabilities: Lease liabilities, net of current portion 109,296 111,027 Liability related to the sale of future royalties 346,776 341,361 Credit facility, net of current portion 407,789 393,183 Total long-term liabilities 863,861 845,571 Commitments and contingencies (Note 7) Noncontrolling interest and stockholders' equity: Common stock, $ 0.001 par value: Authorized 290,000 shares; issued and outstanding 125,572 and 124,376 shares 218 217 Additional paid-in capital 1,846,842 1,806,000 Accumulated other comprehensive income 4,137 4,750 Accumulated deficit ( 1,798,608 ) ( 1,625,523 ) Total Arrowhead Pharmaceuticals, Inc. stockholders' equity 52,589 185,444 Noncontrolling interest 3,486 5,619 Total noncontrolling interest and stockholders' equity 56,075 191,063 Total Liabilities, Noncontrolling Interest and Stockholders' Equity $ 1,013,694 $ 1,139,802 The accompanying notes are an integral part of these unaudited consolidated financial statements. 1 Arrowhead Pharmaceuticals, Inc

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (unaudited) NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES General and Recent Developments Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the "Company") are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference ("RNAi") is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company's RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. The following table presents the Company's current pipeline: Therapeutic Area Name Stage Product Rights Cardiometabolic plozasiran Phase 3 Arrowhead zodasiran Phase 2b Arrowhead olpasiran Phase 3 Amgen Pulmonary ARO-RAGE Phase 1/2a Arrowhead ARO-MMP7 Phase 1/2a Arrowhead Liver GSK-4532990 Phase 2b GSK fazirsiran Phase 3 Takeda and Arrowhead daplusiran/tomligisiran Phase 2 GSK ARO-PNPLA3 Phase 1 Arrowhead ARO-C3 Phase 1/2a Arrowhead ARO-CFB Phase 1/2a Arrowhead ARO-INHBE Phase 1/2a Arrowhead Muscle ARO-DUX4 Phase 1/2a Arrowhead ARO-DM1 Phase 1/2a Arrowhead Central Nervous System (CNS) ARO-ATXN2 Phase 1/2a Arrowhead The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company's principal executive offices are located in Pasadena, California. During the first quarter of fiscal 2025, the Company continued to develop and advance its pipeline and partnered candidates. Several key recent developments include: Submitted a New Drug Application (NDA) to t

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing